Personalized mRNA vaccine for melanoma cuts the risk of recurrence or death by 42% in a late-stage trial
NBC News reported on Friday, Oct. 23, that Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a late-stage trial. The New York Times reported that beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more. Bloomberg reported that leaked data from the highly anticipated trial led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. The reports reviewed do not give the full trial data or a date for regulatory review.
A late-stage trial is the last step before a company asks regulators to approve a treatment, which is why a 42% reduction in recurrence and death risk against standard treatment draws attention from both doctors and investors. Bloomberg’s account of a split between oncologists and the market shows that a medical result and a stock reaction can point in opposite directions.
The reports describe trial results, not an approved treatment, so nothing is available to patients on the strength of these reports alone. Anyone with melanoma should ask their own oncologist about clinical trials and what the data mean for their case.
The medical view, as Bloomberg reports it, is that oncologists cheered the data, and the New York Times describes new hope for patients and further studies in other cancers. On this view, the result is a significant step for personalized cancer vaccines.
The market view, as Bloomberg reports it, is that Wall Street sold off the stocks after the leaked data, even as doctors celebrated. On this view, investors expected more from the results or doubted the commercial picture, and the reports do not say which.
Confirmed across outlets: the vaccine cut the risk of recurrence and death by 42% versus standard treatment in a late-stage trial, per NBC News. Not confirmed: the full data, side effects or when regulators will review it. Watch for the companies’ full trial presentation.
DailyDrop U.S. No. 20 · October 24, 2026 · Evening